Oral surgery procedures in patients on anticoagulants. Preliminary report.
BACKGROUND
Patients who receive oral anticoagulants generally undergo oral surgery procedures, especially teeth extractions. Because the withdrawal of anticoagulant therapy may lead to severe thromboembolic complications, an attempt to perform oral surgery procedures without discontinuation of anticoagulation, based on the published reports, was made.


OBJECTIVE
To present our own experience with the maintenance of anticoagulant therapy with oral coumarin-type drugs and/or acetylsalicylic acid in patients with cardiovascular diseases who undergo oral surgical procedures.


METHODS
The group consisted of 40 patients (12 females and 28 males) aged 39-83 years (mean age 58 years) hospitalised in the 1st Department of Oral and Maxillofacial Surgery in Zabrze from January 2000 to June 2003. The following paper presents the results of the treatment of patients with cardiovascular diseases, who are on oral coumarin-type anticoagulants and/or acetylsalicylic acid, performed without modification of the treatment/anticoagulant therapy.


RESULTS
The level of anticoagulation defined as the INR (International Normalized Ratio) and measured in all patients on the day of surgery ranged from 1.0 to 4.0. Activated Partial Thromboplastin Time (aPTT) was between 26 and 88 seconds, with a reference range in healthy subjects of 42-65 seconds. The prothrombin time ratio ranged from 26% to 100% (N: 80-120%). Only 8% of patients developed minor bleeding complications which were promptly controlled with additional haemostasis.


CONCLUSIONS
Teeth extractions and other oral surgical procedures may be performed without discontinuation of anticoagulants.
Cieślik-Bielewska
Agata
A
1st Department of Oral and Maxillofacial Surgery, Medical University of Silesia, ul. Buchenwaldczyków 19, 41-800 Zabrze, Poland. agatabielecka@poczta.onet.pl
Pelc
Ryszard
R
Cieślik
Tadeusz
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000188:drug therapy; D003374:Coumarins / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D019647:Oral Surgical Procedures; D010314:Partial Thromboplastin Time; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D000925:Anticoagulants; D003374:Coumarins; D010975:Platelet Aggregation Inhibitors; C030123:coumarin; D001241:Aspirin